Xsensio, a Swiss company that is developing the Lab-on-Skin© sensing platform, announced today that it has entered into a know-how and stock purchase agreement with Mayo Clinic.
LAUSANNE, Switzerland, Jan. 31, 2023 /PRNewswire-PRWeb/ -- Xsensio, a Swiss company that is developing the Lab-on-Skin© sensing platform, announced today that it has entered into a know-how and stock purchase agreement with Mayo Clinic for the development of new wearable products based on short term health dynamics in critical care.
Xsensio will work closely with Mayo Clinic subject matter experts who will provide clinical and product development expertise to Xsensio around the use of its proprietary health monitoring technology for critical care. The intent is to further accelerate innovation in the development of next-generation wearable solutions that provide continuous, real-time, on-body monitoring of biochemical data, with the goal of enhancing personalized early detection of rapidly evolving acute events, improving rapid clinical workflow, and enabling remote patient monitoring.
"This collaboration will provide key insights for the use of our proprietary Lab-on-Skin© sensing platform for critical care in the hospital and at home. We are very excited to establish a collaboration with Mayo Clinic," said Esmeralda Megally, CEO and Co-Founder of Xsensio.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
About Xsensio S.A.
Xsensio is an innovation-driven digital health company dedicated to solving one of the biggest challenges in healthcare: the lack of real-time, continuous monitoring of relevant health parameters.
To achieve this vision and ultimately improve patient outcome, Xsensio is building the breakthrough minimally invasive Lab-on-Skin© wearable platform based on a wearable technology capable of offering unique health insight through the continuous and real-time multi-modal analysis of biochemical data.
Media Contact
Esmeralda Megally, Xsensio, 41 791388906, [email protected]
SOURCE Xsensio
Share this article